SCHEMBL809394

SCHEMBL809394

O=C(O)c1ccc(Cl)cc1-c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TSHR P16473 2/20 0.59
TP53 P04637 1/20 0.59
CASP1 P29466 1/20 0.59
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
GRIK1 P39086 2/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SRD5A2 P31213 1/20 0.49
AURKA O14965 1/20 0.48
TPX2 Q9ULW0 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ANO1 Q5XXA6 2/20 0.47
MAPT P10636 1/20 0.47
SERPINE1 P05121 1/20 0.46
PTGES O14684 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7554300 0.90 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL6492374 0.89 DHODH (0.55) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL8248300 0.87 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL6695209 0.86 PRKAB2 (0.53) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL2558658 0.86 AKR1C3 (0.51) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL15330366 0.86 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL6498907 0.86 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL23354242 0.85 ANO1 (0.49) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL6489883 0.85 NPC1 (0.51) ALDH1A1SMN1; SMN2TSHRTP53CASP1
SCHEMBL29979920 0.85 ANO1 (0.49) ALDH1A1SMN1; SMN2TSHRTP53CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
CN-115793391-A Photoresist and application thereof 北京科华微电子材料有限公司 2023-03-14 CN disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
EP-1845122-B1 POLYARYLENE, PROCESS FOR PRODUCING THE SAME, SOLID POLYELECTROLYTE, AND PROTON-CONDUCTIVE FILM JSR CORP (JP) 2011-11-16 EP disclosed
US-7893303-B2 Polyarylene, process for producing the same, solid polyelectrolyte, and proton-conductive film JSR CORPORATION (JP) 2011-02-22 US disclosed
US-20080015389-A1 Polyarylene, Process For Producing The Same, Solid Polyelectrolyte, And Proton-Conductive Film JSR CORPORATION (JP) 2008-01-17 US disclosed
EP-1845122-A1 POLYARYLENE, PROCESS FOR PRODUCING THE SAME, SOLID POLYELECTROLYTE, AND PROTON-CONDUCTIVE FILM JSR Corporation (JP) 2007-10-17 EP disclosed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015389-A1 Polyarylene, Process For Producing The Same, Solid Polyelectrolyte, And Proton-Conductive Film PARG, PUF60, PARN ALDH1A1 3441/4885SMN1; SMN2 1535/4885TSHR 3755/4885
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 ALDH1A1 3828/4885SMN1; SMN2 3850/4885TSHR 1345/4885
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 ALDH1A1 2901/4885SMN1; SMN2 1854/4885TSHR 1272/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 ALDH1A1 1603/4885SMN1; SMN2 1921/4885TSHR 2021/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ALDH1A1 3828/4885SMN1; SMN2 3850/4885TSHR 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.